Interleukin-17 promotes angiogenesis and tumor growth - PubMed (original) (raw)
. 2003 Apr 1;101(7):2620-7.
doi: 10.1182/blood-2002-05-1461. Epub 2002 Oct 31.
Affiliations
- PMID: 12411307
- DOI: 10.1182/blood-2002-05-1461
Free article
Interleukin-17 promotes angiogenesis and tumor growth
Muneo Numasaki et al. Blood. 2003.
Free article
Abstract
Interleukin-17 (IL-17) is a CD4 T-cell-derived proinflammatory cytokine. We investigated the effects of locally produced IL-17 by tumors as a means to evaluate its biologic function. Although recombinant IL-17 protein or retroviral transduction of IL-17 gene into tumors did not affect in vitro proliferation, IL-17 transfectants grew more rapidly in vivo when compared with controls. Immunostaining for Factor VIII revealed that tumors transduced with IL-17 had significantly higher vascular density when compared with controls. IL-17 indeed elicited neovascularization in rat cornea. In addition, angiogenic activity present in the conditioned media of CD4 T cells was markedly suppressed by neutralizing monoclonal antibody to IL-17. IL-17 had no direct effect on the growth of vascular endothelial cells, whereas IL-17 significantly stimulated migration. IL-17 also markedly promoted the cord formation of vascular endothelial cells. In addition, IL-17 up-regulated elaboration of a variety of proangiogenic factors by fibroblasts as well as tumor cells. These findings reveal a novel role for IL-17 as a CD4 T-cell-derived mediator of angiogenesis that stimulates vascular endothelial cell migration and cord formation and regulates production of a variety of proangiogenic factors. Furthermore, they suggest that inhibition of biologic action of IL-17 may have therapeutic benefits when applied to angiogenesis-related disorders.
Similar articles
- Interleukin-8 as a macrophage-derived mediator of angiogenesis.
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Koch AE, et al. Science. 1992 Dec 11;258(5089):1798-801. doi: 10.1126/science.1281554. Science. 1992. PMID: 1281554 - Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic.
Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, Barra A, Tucci M, Parise G, Vincenti V, Granger HJ, Viglietto G, Persico MG. Ziche M, et al. Lab Invest. 1997 Apr;76(4):517-31. Lab Invest. 1997. PMID: 9111514 - Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.
Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, Polverini PJ. Nör JE, et al. Cancer Res. 2001 Mar 1;61(5):2183-8. Cancer Res. 2001. PMID: 11280784 - Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor.
Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Campbell CL, et al. Int J Cancer. 1999 Mar 15;80(6):868-74. doi: 10.1002/(sici)1097-0215(19990315)80:6<868::aid-ijc12>3.0.co;2-1. Int J Cancer. 1999. PMID: 10074920 - IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. Numasaki M, et al. J Immunol. 2005 Nov 1;175(9):6177-89. doi: 10.4049/jimmunol.175.9.6177. J Immunol. 2005. PMID: 16237115
Cited by
- Signaling pathways and targeted therapy for rosacea.
Yang F, Wang L, Song D, Zhang L, Wang X, Du D, Jiang X. Yang F, et al. Front Immunol. 2024 Sep 16;15:1367994. doi: 10.3389/fimmu.2024.1367994. eCollection 2024. Front Immunol. 2024. PMID: 39351216 Free PMC article. Review. - Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series.
Li YJ, Msaouel P, Campbell M, Hwu P, Diab A, Kim ST. Li YJ, et al. RMD Open. 2024 Aug 30;10(3):e004308. doi: 10.1136/rmdopen-2024-004308. RMD Open. 2024. PMID: 39214611 Free PMC article. - Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives.
Ye Z, Cheng P, Huang Q, Hu J, Huang L, Hu G. Ye Z, et al. Front Immunol. 2024 May 22;15:1388176. doi: 10.3389/fimmu.2024.1388176. eCollection 2024. Front Immunol. 2024. PMID: 38840908 Free PMC article. Review. - Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma.
Sussman TA, Severgnini M, Giobbie-Hurder A, Friedlander P, Swanson SJ, Jaklitsch M, Clancy T, Goguen LA, Lautz D, Swanson R, Daley H, Ritz J, Dranoff G, Hodi FS. Sussman TA, et al. Front Oncol. 2024 May 15;14:1395978. doi: 10.3389/fonc.2024.1395978. eCollection 2024. Front Oncol. 2024. PMID: 38812776 Free PMC article. - IL-17 in wound repair: bridging acute and chronic responses.
Mu X, Gu R, Tang M, Wu X, He W, Nie X. Mu X, et al. Cell Commun Signal. 2024 May 27;22(1):288. doi: 10.1186/s12964-024-01668-w. Cell Commun Signal. 2024. PMID: 38802947 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials